AC-262536

Overview

AC-262536 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) with an azabicyclooctane naphthalene-carbonitrile structure. It acts as a partial AR agonist, showing tissue-selective anabolic effects in preclinical models. No human trials have been conducted, and it is not FDA-approved. SARMs are prohibited in athletic competition under WADA category S1.2.

Mechanism of Action

AC-262536 was identified in a functional cell-based reporter assay as a potent, selective androgen receptor ligand acting as a partial agonist relative to testosterone. Unlike full AR agonists, it produces tissue-selective activation, preferentially stimulating anabolic pathways over androgenic endpoints. This selectivity profile is characteristic of the SARM class.

Research Summary

No human data exist. All pharmacology derives from a single 2008 preclinical publication. In castrated male rats dosed chronically for two weeks, AC-262536 significantly increased levator ani muscle growth and suppressed elevated luteinizing hormone, while producing only weak effects on prostate and seminal vesicle weight compared to testosterone. The compound has also been included in validated analytical panels for SARM residue surveillance in bovine muscle tissue, reflecting its presence in food-safety monitoring rather than therapeutic development.

Vendors selling AC-262536

Scored vendors carrying AC-262536, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• No human toxicology data exist
• Prohibited in athletic competition (WADA S1.2 SARM class ban)
• General SARM-class concerns: unknown hepatic, cardiovascular, and endocrine risks
• Potential for product contamination in unregulated gray-market sources
• Suppression of luteinizing hormone observed in castrated rats

Compare AC-262536 with Others

Research References

• Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. 2008. PMID 18164613.
• AC-262536 - PubChem Compound Summary (CID 44512434).
• AC-262536 - NCATS Inxight Drugs (UNII U8VS41J5O6).
• AC-262536 - DrugBank Online (DB13935).

Frequently asked questions

Where can researchers source AC-262536?

1 vendor with Disclosed Labs trust grades currently list AC-262536, including Kimera Chems. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/ac-262.

How does AC-262536 work?

AC-262536 was identified in a functional cell-based reporter assay as a potent, selective androgen receptor ligand acting as a partial agonist relative to testosterone. Unlike full AR agonists, it produces tissue-selective activation, preferentially stimulating anabolic pathways over androgenic endpoints. This selectivity profile is characteristic of the SARM class.

What does the research say about AC-262536?

No human data exist. All pharmacology derives from a single 2008 preclinical publication. In castrated male rats dosed chronically for two weeks, AC-262536 significantly increased levator ani muscle growth and suppressed elevated luteinizing hormone, while producing only weak effects on prostate and seminal vesicle weight compared to testosterone. The compound has also been included in validated analytical panels for SARM residue surveillance in bovine muscle tissue, reflecting its presence in food-safety monitoring rather than therapeutic development.